Intro:

CEN www.cenes.com - recently got large institutional ownership - Glaxo Smith Kline. An approx 2.5 bagger in 2003 from 3p to 8p, that is now in much better shape going forward in 2004. Has previously reached over 3.


Broker recommendations recently turned to:

ING Financial Markets 17-Oct-03 BUY
Eden Group 4-Dec-03 BUY
Evolution Beeson Gregory 9-Dec-03 BUY


Products:
Morphine Substitute. Huge worldwide market! - hence Glaxo.

The company is focused on the development of morphine-6-glucuronide (M6G) and CNS 5161 in the indications of acute and chronic pain.

Phase two and three trials underway for various large market products. etc

Major Institutional share ownership:

249.20m 1p Ords
Avlar Bioventures Fund II 9.14%
Active Capital Trust PLC 8.51%
Barclayshare Noms Ltd 6.10%
Prudential 5.82%
GlaxoSmithKline 5.33%
NY Nominees Ltd 4.51%
HSBC Global Cust Noms 764685 3.21%
Pershing Keen Noms Ltd 3.15%
A G Goodman 5.78%(dup) - Director
Other Dirs 0.16

Outlook:

(30/09/03) Interim Report: ch - "The termination of the CeNeS/Elan relationship, our pain-focused late stage pipeline and our strong cash position mean we are well positioned to move forward"



Any thoughts.

CeNeS Pharmaceuticals PLC
08 January 2004


CeNeS announces appointment of Alan Smith as non-executive director

Cambridge, UK, 8th January 2004 - CeNeS Pharmaceuticals plc (LSE: CEN) ('CeNeS'
or 'the Company') today announced the appointment of Alan Smith as a
non-executive director of CeNeS Pharmaceuticals plc. Alan Smith has had
extensive experience at senior executive and non-executive level in listed
companies and is currently Chairman of Acambis plc and Avlar Bioventures
Limited.

Commenting on the appointment, Alan Goodman, Chairman of CeNeS said, 'I am
delighted to welcome Alan Smith to the CeNeS Board. His experience of
successfully growing a biotechnology company combined with his general listed
company expertise will be of great value to CeNeS. This appointment is also
another step forward for CeNeS as the company progresses its corporate
development. The Board believe that CeNeS is well positioned to deliver value to
shareholders in the future.'

For more information please contact:

CeNeS Pharmaceuticals plc

Neil Clark

Tel: +44 (0)1223 266466

Fax: +44 (0)1223 266467


Capital MS & L

Mary Clark

Tel: +44 (0) 20 7878 3245

Fax: +44 (0) 20 7878 3184


Notes to Editors:

CeNeS is a biopharmaceutical company specialising in the discovery, development
and commercialisation of drugs for the treatment of pain and disorders of the
central nervous system. The company is based in Cambridge, England. For further
information visit
www.cenes.co.uk
< http://www.cenes.co.uk/>
.

Alan Smith, 58, is a member of the Chartered Institute of Public Finance and
Accountancy He joined the Board of Acambis plc on 3 November 1995 as a
non-executive Director and was appointed non-executive Chairman on 20 May 1999.
He was Group Managing Director of Anglian Water plc until December 1997 and is
currently Chairman of Avlar Bioventures Limited. Avlar Bioventures Limited
manages Avlar Bioventures Fund II Limited Partnership which has an interest in
22,786, 596 ordinary 1 pence shares in the Company representing 9.1 per cent of
the current issued share capital of the Company.

CeNeS confirms there are no other details to be disclosed under paragraph (f) of
Schedule 2 of the AIM rules in relation to the appointment of Alan Smith.

CEN is on the up again :))

If it holds 10.75 then the next stop is 33p imop

Why 33p Scottie?

I have a nice write up on CEN that came out in last weeks Jan 2004 edition of Invivo Europe Journal - the biotech industry's trade journal.
Anyone want a copy - 3 pages on a word doc scan which may need to have the % increased to read it comfortably - email me on
ninadan@hotmail.com

ticker - have a look at the chart!

its looking stonking
newsflow could be good
Expect Nomura to do some serious ramping.

Pharmaceutical companies are always liable to fly, is the general consensus this one will?

I don't mind it not flying overnight so long as we have a steady rise each day.

Agreed ticker, just like it's moved for the last five trading days - +.25, +.25, +.25, +.75, +1 --------and today?

Up another .25 today. Personally this is the kind of little penny share I love, it just keeps slowly ticking up. These other volatile penny lunatics are a nightmare to deal with!

after reading KAT's doc from post no7, think this is a very risky punt...widows and orphans etc....but will follow this one, can't help bieng a cynical o.b., pharma's do fly - but both ways.

Another nice tick up today and looking strong for next week

Glad to see everybody is happy! - but Might be time to take some profit and wait for a retracement - then buy more!? Difficult call.

My other punt FFA on the Penny share 20004 punt is also up > 30% this year so far with more to go. Planestation group looks interesting in the interim.
Will be doing some more research over the weekend. Good luck folks.

had a good write up in last months scsw
www.scsw.co.uk

This stock has really taken off since Friday without any news. Has anyone any ideas why??

Don't know ticker, but there is some serious buying going on again this morning.

I suppose we don't really need a reason if it goes on up without news :)

Just gone up again today on no news - I wish the rest of my portfolio was like this!